Scarica l'app Stockscreener
0.6988
0.60%
-0.0042
Precedente Chiudi:
$0.703
Aprire:
$0.7199
Volume 24 ore:
18,532
Relative Volume:
0.01
Capitalizzazione di mercato:
$2.98M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-15.05%
1M Prestazione:
-37.61%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.67
$0.72
Intervallo di 1 settimana:
$0.67
$0.90
Portata 52W:
$0.67
$4.80
Polyrizon Ltd Stock (PLRZ) Company Profile
Confronta PLRZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
0.70 | 2.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.85 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.11 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.02 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.96 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.31 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Polyrizon Ltd Borsa (PLRZ) Ultime notizie
Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses - Marketscreener.com
Polyrizon advances naloxone intranasal delivery studies By Investing.com - Investing.com South Africa
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform - The Manila Times
Revolutionary Naloxone Delivery: Polyrizon Targets $2.4B Opioid Treatment Market - StockTitan
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - The Manila Times
Polyrizon Releases Comprehensive 2024 Financial Report: Key Details Now Available - StockTitan
Polyrizon begins preclinical studies for nasal opioid overdose treatment By Investing.com - Investing.com Australia
Polyrizon Launches Preclinical Trials for Intranasal Naloxone - TipRanks
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform - The Manila Times
Polyrizon initiates preclinical studies for intranasal naloxone - TipRanks
Polyrizon Begins Preclinical Studies for Next-Gen Naloxone Delivery - StockTitan
Polyrizon appoints new board member Liron Carmel - MSN
Polyrizon Ltd. Announces Filing of Divisional Patent Application for Its Innovative Trap & Target (T&T) Intranasal Drug Delivery Platform - Marketscreener.com
Polyrizon files patent for nasal drug delivery tech - MSN
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform - Marketscreener.com
Game-Changing Nasal Drug Tech Could Transform Treatment of Seizures and Overdoses - StockTitan
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ) - ACCESS Newswire
Polyrizon Ltd (NASDAQ: PLRZ) Declined -5.41%, What’s Next? Don’t Panic - Stocks Register
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - The Manila Times
Polyrizon Ltd. Commences GMP Manufacturing Preliminary Process for Its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - Marketscreener.com
Polyrizon Advances PL-14 Allergy Blocker Manufacturing, Eyes $23B Nasal Spray Market - StockTitan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Polyrizon (PLRZ) Stock Climbs After Patent Publication Update - Stocks Telegraph
Polyrizon Shares Rise After Publication of National Patent Application - MarketWatch
Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today? - Benzinga
Patents and new EV’s have these small caps perking - RagingBull
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - The Manila Times
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
Full Stock Market News from 2024-12-21 - StockTitan
SPRC stock touches 52-week low at $0.21 amid sharp decline - Investing.com India
Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial - MSN
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs - The Manila Times
Polyrizon Strengthens Clinical Leadership Ahead of Key 2025 PL-14 Trial, Appoints Regulatory Expert - StockTitan
U.S. Stocks Drop Sharply with Losses Across Major Sectors, Amazon and American Express Lead Declines - mediahousepress
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com India
Nektar Therapeutics (NKTR) Stock Plummets Amidst Biotech Sector Decline - GuruFocus.com
TFSA: 3 Top TSX Stocks for Your $7,000 Contribution - Yahoo Canada Finance
Wall Street-Heavily Traded - WDRB
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Strategic DealSends Polyrizon (PLRZ) Shares To New Heights - Stocks Telegraph
Stellantis moves up launch of hybrid Ramcharger as EV demand cools - Yahoo Canada Finance
Polyrizon Ltd Azioni (PLRZ) Dati Finanziari
Non sono disponibili dati finanziari per Polyrizon Ltd (PLRZ). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
5.68%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):